Cardiovascular therapeutic devices (CTDs) remain limited by thrombotic adverse events.
Current antithrombotic agents limit thrombosis partially, often adding to bleeding. The …

Disclaimer In an effort to expedite the publication of articles, AJHP is posting manuscripts
online as soon as possible after acceptance. Accepted manuscripts have been peer …

At present, the Impella range of devices (Abiomed) are the only percutaneous transvalvular
microaxial pumps that are approved for clinical use in the United States and Europe. The …

The mortality rate of postcardiotomy cardiogenic shock after cardiovascular surgery is quite
high, and the only way to avoid this serious complication is to initiate a preemptive strategy …

In the human body, bleeding and blood clotting maintain a delicate balance, particularly
during the use of short-and long-term blood contacting medical devices. The management of …